Sensus Healthcare (NASDAQ:SRTS – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01), Zacks reports. Sensus Healthcare had a net margin of 22.54% and a return on equity of 17.99%.
Sensus Healthcare Price Performance
Shares of Sensus Healthcare stock traded down $2.73 during trading hours on Thursday, hitting $6.26. The company had a trading volume of 1,539,660 shares, compared to its average volume of 313,849. Sensus Healthcare has a twelve month low of $2.91 and a twelve month high of $9.33. The company has a market cap of $102.60 million, a P/E ratio of 10.95 and a beta of 1.24. The company’s 50-day moving average is $7.49 and its two-hundred day moving average is $6.89.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the company. Maxim Group increased their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. HC Wainwright lifted their price objective on Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, November 18th. Finally, Lake Street Capital began coverage on shares of Sensus Healthcare in a report on Friday, January 31st. They set a “buy” rating and a $18.00 target price on the stock.
About Sensus Healthcare
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Recommended Stories
- Five stocks we like better than Sensus Healthcare
- The 3 Best Fintech Stocks to Buy Now
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- How to Find Undervalued Stocks
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- How to Read Stock Charts for Beginners
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.